ArticleEuropean thyroid journal2026
Interference in thyroid function tests using the electrochemiluminescence immunoassay.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Electrochemiluminescence immunoassays (ECLIAs) are widely used for thyroid function testing but may be affected by rare assay interferences that can lead to misdiagnosis. We aimed to investigate the frequency and types of assay interferences in thyrotropin (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) measurements using the Roche ECLIA. Methods: Between 2019 and 2023, 124,615 patients underwent thyroid function testing. Assay interference was suspected in 283 cases based on clinical-laboratory mismatch, thyroid hormone imbalance, or discrepancies between assay methods. Further validation assessed potential interferences. Results: Of the total tests (TSH: 124,609; FT4: 116,012; and FT3: 83,044), 71 interference cases were confirmed (TSH: 11 (0.009%), FT4: 6 (0.005%), and FT3: 53 (0.064%)). FT3 interferences were mainly due to idiotype and anti-streptavidin antibodies. Macro-TSH was detected in six cases and often led to unnecessary levothyroxine treatment. Furthermore, most interferences were detected by recognizing hormonal imbalances rather than clinical symptoms. Conclusion: FT3 tests are most prone to assay interference. Awareness of inter ference patterns and close collaboration between physicians and laboratory staff are essential to prevent diagnostic errors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.